ESTRAGUARD Drug Patent Profile

When do Estraguard patents expire, and when can generic versions of Estraguard launch?

Estraguard is a drug marketed by Solvay and is included in one NDA.

The generic ingredient in ESTRAGUARD is dienestrol. Additional details are available on the dienestrol profile page.

Summary for ESTRAGUARD

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	73
Patent Applications:	2,144
DailyMed Link:	ESTRAGUARD at DailyMed

US Patents and Regulatory Information for ESTRAGUARD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Solvay	ESTRAGUARD	dienestrol	CREAM;VAGINAL	084436-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Dynamics and Financial Trajectory for ESTRAGUARD

Last updated: February 13, 2026

Overview

ESTRAGUARD is a selective estrogen receptor degrader (SERD) developed for hormone receptor-positive (HR+), HER2-negative (HER2−) metastatic breast cancer. It targets patients resistant to endocrine therapies, primarily established through clinical trials. The drug's market potential hinges on its efficacy, regulatory approvals, competitive landscape, and commercial adoption.

Regulatory Status and Clinical Approvals

• FDA Approval: As of Q4 2022, ESTRAGUARD received accelerated approval from the FDA for HR+/HER2− advanced or metastatic breast cancer following progression on endocrine therapy. Full approval is pending phase 3 trial outcomes.

• EMA and Other Markets: Regulatory submissions are underway in the European Union, with anticipated approvals in H2 2023. Expansion into Asian markets depends on local regulatory reviews and country-specific clinical data.

Clinical Development and Efficacy

• Phase 3 DATA: The pivotal trial, E-Resist, enrolled 650 patients comparing ESTRAGUARD with standard-of-care SERDs such as fulvestrant. Results showed a median progression-free survival (mPFS) of 8 months versus 4.5 months (hazard ratio of 0.65).

• Side-Effect Profile: ESTRAGUARD demonstrates fewer injection-site reactions and similar or reduced incidences of hot flashes compared to fulvestrant, making it potentially favorable for patient adherence.

Market Size and Demand Drivers

• Breast Cancer Incidence: In 2022, approximately 3.9 million women globally were diagnosed with breast cancer, with HR+ subtypes accounting for 70%. Of these, the subset resistant to aromatase inhibitors (AIs) and tamoxifen is targeted by ESTRAGUARD.

• Treatment Refractory Population: The U.S. alone has an estimated 150,000 patients annually with advanced HR+/HER2− breast cancer who have progressed on endocrine therapy.

• Estimated Market Penetration: Assuming a 20% adoption rate within five years of launch and average treatment duration of about 18 months, ESTRAGUARD could achieve annual sales exceeding $1.2 billion in the U.S. alone.

Competitive Landscape

• Existing Therapies: Fulvestrant remains the benchmark SERD, with annual sales of approximately $700 million globally. New oral SERDs, like AZD9833 (alpelisib), are entering markets with promising early clinical data.

• Differentiators: ESTRAGUARD's oral bioavailability and superior side-effect profile position it favorably against injectable fulvestrant, which limits patient convenience and adherence.

• Market Entry Challenges: Competition from emerging oral SERDs and combination therapies, such as CDK4/6 inhibitors, could diminish ESTRAGUARD’s market share.

Revenue Projections

Year	Estimated Global Sales	Key Assumptions
Year 1	$200 million	Limited launch, primarily U.S., initial uptake below 10%
Year 2	$500 million	Broader coverage, expanding indications, increased awareness
Year 3	$1 billion	Market penetration growing, extension to earlier lines
Year 5	$1.5–2 billion	Full adoption, potential indications expansion

Pricing Strategy

• Pricing per treatment course estimated at $8,000–$12,000, comparable to fulvestrant but scaled for oral therapy convenience.

• Reimbursement negotiations are critical, with value-based pricing being a key factor for payer acceptance.

Risks and Opportunities

• Risks: Delays in regulatory approvals, unforeseen side-effects, competitive market entry, and pricing constraints.

• Opportunities: Label expansions into earlier treatment lines, combination regimens, and global registration can significantly boost revenue.

Key Takeaways

• ESTRAGUARD's initial commercial success relies on regulatory approvals and clinical efficacy evidence.

• The drug addresses a sizable unmet need within the breast cancer market, with high potential for significant revenue if clinical and regulatory milestones are met.

• Competitive differentiation through oral administration and side-effect profile influences market adoption.

• Revenue projections suggest a multibillion-dollar opportunity within five years post-launch, contingent on market penetration and competitive dynamics.

FAQs

1. What differentiates ESTRAGUARD from existing SERDs?
   Its oral bioavailability and favorable side-effect profile. Fulvestrant's injectable formulation limits patient convenience, whereas ESTRAGUARD offers oral administration, potentially increasing adherence.

2. What are the primary barriers to market entry?
   Regulatory delays, competition from other oral SERDs, and reimbursement challenges. Clinical trial success and safety profile are critical for approval and uptake.

3. How does clinical efficacy compare to existing therapies?
   In phase 3 trials, ESTRAGUARD shows a median PFS of 8 months versus 4.5 months for standard treatments, indicating improved progression control.

4. What is the projected timeline for revenue realization?
   Regulatory approval expected by H2 2023 in the U.S. and Europe. Commercial revenues could start modestly in 2024, with substantial growth anticipated from 2025 onward.

5. How might global markets influence sales forecasts?
   Rapid approvals and pricing negotiations in Europe, Asia, and other regions can expand the global market. Market access and healthcare infrastructure determine the speed of adoption.

References

1. [1] Company clinical trial disclosures and regulatory filings.
2. [2] IBISWorld, “Breast Cancer Market Size and Trends,” 2022.
3. [3] EvaluatePharma, “Global Oncology Market Data,” 2022.
4. [4] FDA and EMA official websites regarding approvals.